Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
320
NCT00802594
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 31, 2001
Completion: Nov 30, 2004
NCT00803933
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Start: Feb 28, 2003
Completion: Jun 30, 2005
NCT00302341
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Phase: Phase 3
Start: May 31, 2006
Completion: Dec 31, 2008
NCT00408369
Prophylactic Antimalarial Activity of DB289 in Volunteers
Phase: Phase 1/2
Start: Nov 30, 2006
Completion: Nov 30, 2007
NCT00619346
Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects
Phase: Phase 1
Start: Nov 30, 2007
Completion: Feb 28, 2009
NCT04697290
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
Phase: Early Phase 1
Role: Collaborator
Start: Mar 10, 2022
Completion: Jun 10, 2023